Analyst Price Targets — DMAC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 7, 2024 9:07 am | Bill Chappell | Truist Financial | $10.00 | $4.42 | Benzinga | This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday |
| October 7, 2024 6:05 am | Matthew Caufield | H.C. Wainwright | $7.00 | $4.36 | TheFly | DiaMedica Therapeutics initiated with a Buy at H.C. Wainwright |
| March 21, 2024 9:10 am | Alex Nowak | Craig-Hallum | $8.00 | $2.69 | StreetInsider | DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $8 at Craig-Hallum |
Latest News for DMAC
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica's common stock to a newly hired non-executive employee whose employment…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR). This is the first…
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes,…
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026. Jefferies Global Healthcare Conference Date: Thursday, June…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DMAC.
U.S. House Trading
No House trades found for DMAC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.